reason report
refresh view women health market pt
bottom line refresh view endometriosi
em uterin fibroid uf market incorpor slower
expect ramp endometriosi potenti higher penetr
uf lower complianc rate indic
maintain prior peak market share estim obseva
em uf chang market model delay
em launch reflect temporari enrol
hold due lower estim linzagolix
em leav peak sale uf essenti
unchang addit assum royalty-bas econom
structur linzagolix appropri reflect manag
state strategi thu lower price target obsv
reiter outperform rate compani also
recent provid inform regard impact
importantli timelin clinic catalyst year remain intact
includ readout second phase trial primros uterin
fibroid result phase prolong trial
pre-term labor howev compani put hold
screen random patient two on-going
endometriosi trial edelweiss although patient current
treatment continu program obseva guid extend cash
runway previous
two phase endometriosi trial put hold due
given expect logist challeng initi screen
uncertainti continu treatment random patient
pandem obseva decid place
voluntari hold screen random patient
edelweiss trial patient alreadi random
treat continu receiv treatment monitor compani
clarifi remain readi commit resum patient screen
random situat permit remain unclear
trial could resum enrol guidanc quarter
longer cash runway suggest compani like expect hold
last quarter previous expect linzagolix launch em
late push launch reflect
methodolog dcf cash flow use
wacc
net debt total capit
gener
year price history/av daili volume mil obsv
compani inform svb leerink llc research
revenu
pleas refer page import disclosur price chart analyst certif
rx trend deriv iqvia inc
trial hold expens reduct effort extend cash runway
delay spend edelweiss trial
recent reduct staff employe benefit obseva expect
substanti lower cash burn next quarter
cash cash equival end potenti addit
borrow primros success
oxford credit facil compani expect fund oper
expens
moder view market potenti gnrh
antagonist endometriosi lesser extent uterin
fibroid follow abbvi op latest guidanc orilissa
continu feedback weve receiv medacorp physician
refresh view endometriosi uterin fibroid
market slow ramp orilissa endometriosi highlight
difficulti penetr market current offer
moder assumpt growth trajectori penetr
peak penetr gnrh antagonist also reduc
addit lower averag treatment durat
class given consist trend month-to-month
refil rate reflect iqvia script result forecast
world-wide non-adjust sale linzagolix endometriosi came
peak
uterin fibroid physician feedback arguabl larger
unmet need lower respons rate current standard-of-car
endometriosi indic us market potenti could greater
previous thought increas peak penetr gnrh
antagonist reflect updat view
mostli off-set lower assum treatment durat indic
well forecast world-wide non-adjust sale linzagolix uf
came
peak
also chang econom linzagolix model
reflect potenti partnership compani seek pt
given recent comment manag strategi
seek commerci partner linzagolix chang base case
model royalty-bas deal royalti us
ex-u market eventu structur partnership remain
uncertain term agre obseva could significantli
differ assumpt believ base case reflect
industri standard royalti structur could addit profit share
mileston obseva could get howev includ
time assum royalty-bas partnership
remov sale market expens linzagolix
assum obseva collabor larg pharma compani
much stronger expertis market capabl remov
probability-of-success po adjust commerci
execut risk new assumpt expect obseva
rel lower requir capit near term
rais
altogeth chang lower price target obsv
lead asset linzagolix gener posit phase data uterin fibroid
data profil combin time market among gnrh antagonist yield
sale estim non-risk-adjust sale upsid could come
linzagolix uniqu product characterist add-back therapi flexibl daili dose
indic lack food effect depend whether subsequ phase
studi discern impact nevertheless believ market support multipl
product class obsv also target anoth larg high unmet need market pre-term
labor repres upsid valuat current attribut littl
valuat given manag recent comment seek commerci
partnership assum obseva receiv royalti world-wide linzagolix sale
rate obsv outperform pt
pt base dcf analysi forecast cash flow use
discount rate termin valu wacc rang phase
compani coverag univers myov itrm
risk valuat includ unsuccess regulatori action linzagolix and/or data
readout linzagolix may less competit elagolix relugolix elagolix
head start may preclud uptak linzagolix greater extent current expect
food effect add-back therapi flexibl advantag may reson physician
potenti restrict payer environ gnrh antagonist class and/or long-term
safeti class may turn wors current expect
brand
type event
event trial detail
date known
up/down
expect
top-line data phase primros trial
mileston
phase prolong data full patient
svb leerink llc equiti research compani file
compani report svb leerink research
number except per share data
revenu uf
revenu endometriosi
prepaid expens current asset
furnitur fixtur equip pp
payabl current liabil
current portion long-term debt
adjust reconcil ni net cash oper
increas /decreas receiv
increas /decreas prepaid expens defer cost long term-asset
increas payabl current liabil
increas accru expens
decreas increas work capit
use rental deposit
payment plant equip
acquisit licens
net invest
proce issu share equiti secur
payment share issuanc cost
proce issuanc debt
payment defer cost financ activ
net financ
net chang equival
effect exchang rate chang cash cash equival
chang work capit
